First Approval Globally For Gilteritinib, In Japan For AML

 
• By Ian Haydock

First nod globally for Astellas's FLT3 inhibitor set to further increase competition in AML space, but commercial opportunity in  launch market Japan looks set to be limited.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.
FIRST APPROVAL FOR ASTELLAS'S AML DRUG, IN JAPAN • Source: Shutterstock

More from Japan

More from Focus On Asia